ArticleMemorias do Instituto Oswaldo Cruz2025
The 50th Anniversary Conference - Caxambu 2024.
Article in Memorias do Instituto Oswaldo Cruz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease (CD), caused by Trypanosoma (Schizotrypanum) cruzi, remains a major global health concern, particularly in Latin America, where millions are at risk. To mark five decades of Chagas research, the Brazilian Society of Protozoology (SBPz) hosted a four-day conference held in Caxambu, Minas Gerais, Brazil, from November 3 to 7, 2024. The meeting brought together world-renowned experts from diverse disciplines whose work has significantly advanced the boundaries of CD studies. Key discussions focused on the parasite's genetic and metabolic adaptability, with special emphasis on genomic compartmentalisation, RNA processing, and metabolic flexibility essential for survival and pathogenesis. New insights into host-parasite interactions highlighted inflammatory and vascular remodelling processes that drive parasite dissemination and disease progression, especially in cardiac tissue. In the area of drug development, researchers noted treatment limitations, the urgency for novel therapeutic candidates, and ongoing clinical trials assessing alternative regimens of benznidazole (BZN) and nifurtimox (NFX). Progress in biomarker discovery and vaccine development was also discussed as pivotal to improving disease diagnosis, prognosis, and prevention. Beyond laboratory research, the meeting highlighted the importance of science communication and public health engagement. Outreach initiatives and educational exhibitions were showcased as tools to raise awareness and enhance access to disease diagnosis and treatment. Altogether the integration of multidisciplinary approaches from molecular biology to public policy underscores the enduring commitment to combating CD through research, collaboration, and innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.